Opinion: Artificial intelligence could be a crucial multiplier in the fight against malaria. Researchers from Medicines for Malaria Venture explore how to harness its power while ensuring endemic-coun...

Vielä maa- ja metsätalousvaliokunnan infossa metsästyslain muutoksesta kansanedustajat antoivat ristiriitaista tietoa siitä, lisättiinkö ja jäikö listalle karhun ja ilveksen ohella myös saukko – ja la...

MMV’s technical support helps Swipha deliver malaria medicines to pregnant Nigerian women

MMV is proud to announce its new partnership with South Korean biotechnology leader Shaperon to advance game-changing, nanobody treatments for malaria prevention. Nanobody therapeutics are a new generation of medicines that can deliver big benefits via tiny molecules. Much smaller in size than conventional monoclonal antibodies, these next-generation agents designed for seasonal malaria chemoprevention promise improved stability, precision targeting and cost-effectiveness. This innovation could transform malaria prevention strategies and make treatments more accessible worldwide. Read the press release: https://www.mmv.org/newsroom/news-resources-search/shaperon-and-mmv-join-forces-advance-game-changing-cost-effective-0

Siete anche voi del Generale MMV Pronto??

MMV and Novartis have announced positive Phase 3 results for a novel malaria medicine, GanLum. If approved, GanLum would be the first major non-artemisinin-based innovation since 1999, with the potential to block transmission and kill drug-resistant parasites Its novel ingredient, ganaplacide, has a new mechanism of action, discovered after screening more than 2.3 million molecules. Novartis plans to seek regulatory approval for the medicine as soon as possible. This milestone was made possible through the WANECAM 2 consortium, co-funded by European & Developing Countries Clinical Trials Partnership (EDCTP), with support from the European Union and the Swedish International Development Cooperation Agency (Sida). Additional funding was provided by the Deutsche Zentrum für Luft- und Raumfahrt and the Department of Health and Social Care. The project was also made possible thanks to the generous support of MMV’s donors, including the Gates Foundation the Foreign, Commonwealth and Development Office Australian Department of Foreign Affairs and Trade Swiss Agency for Development and Cooperation and USAID. Read the full press release: https://www.mmv.org/newsroom/news-resources-search/phase-3-trial-next-generation-malaria-treatment-ganaplacide-lumefantrine

'Ending the echo' highlights the work of the Partnership for Vivax Elimination (PAVE) in conducting feasibility studies on new tools for P. vivax radical cure. From Ethiopia to Indonesia, and Papua New Guinea to Peru and Vietnam, PAVE is studying the use of a point-of-care G6PD test with single-dose tafenoquine and shorter-course, higher-dose primaquine. PAVE thanks Unitaid for supporting this work. Watch the entire film here: https://www.youtube.com/watch?v=P7b5GZoL25k

Wie berichtet wird Schlager Radio im Frühjahr 2026 die bisherigen UKW-Frequenzen von 80s80s Radio in Mecklenburg-Vorpommern übernehmen. Das hat jetzt auch die Medienanstalt Mecklenburg-Vorpommern (MMV) offiziell bestätigt. Die Frequenzen werden dem Veranstalter für die Dauer von zehn Jahren zugewiesen. Die bisherige Zulassung der radio B2 GmbH zur Veranstaltung und Verbreitung eines 24-stündigen kommerziellen lokalen/regionalen Hörfunkprogramms in den Stadtgebieten Schwerin, Rostock, Wismar, Greifswald und Stralsund sowie in der Region Fischland-Darß-Zingst und südliche Boddenküste wurde mit Wirkung ab dem 1.

YouTube video by BecauseImBored1